Have ICD-10 Coding Practices Changed Since 2015?

Usage of ICD-10 codes in administrative data has continued to shift since mandatory adoption in 2015. Identifying changing patterns in coding behavior is imperative in producing reliable analyses and robust conclusions. We examined the granularity of ICD-10 coding over time in a cohort selected from the IBM Explorys Therapeutic Dataset, which contains the records of over 60 million patients.

Hypothesis-Free Search for Connections between Birth Month and Disease Prevalence in Large, Geographically Varied Cohorts.

We have sought to replicate and extend the Season-wide Association Study (SeaWAS) of Boland, et al. in identifying birth month-disease associations from electronic health records (EHRs). We used methodology similar to that implemented by Boland on three geographically distinct cohorts, for a total of 11.

Results of a multilateral approach to donation-transplantation process in Hungary in the past 2 years.

Hungarotransplant Public Service Corporation, the national organ exchange organization, was established in 2001. The assessment of donation- and transplantation-related data allows the evaluation of the current situation and future trends. The donor reports show involvement of new hospitals and an increase in reported donors.

Effect of etoposide on the pharmacokinetics of methotrexate in vivo.

The effect of etoposide on the pharmakokinetics of methotrexate (MTX) was examined in vivo. High-dose (5g/m2/24 h) MTX therapy was combined with two etoposide (100mg/m2/ 1 h) infusions as a part of the medulloblastoma protocol developed in our department. Vepesid therapy was administered in two different schedules.

Recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia in children with malignant solid tumours.

This prospective, randomised pilot study was designed to evaluate safety, feasibility and efficacy of recombinant human erythropoietin (rhEPO) in the prevention and treatment of chemotherapy-induced anaemia in children with solid tumours. 20 children (age 4-18 years) undergoing cyclic combination chemotherapy were randomised either to a control group or to receive rhEPO at a dose of 150 U/kg/dose subcutaneously three times/week for a minimum of 12 weeks or three chemotherapy cycles. Of 15 evaluable patients, 8 were randomised to the rhEPO group and 7 to the control group.